0.00Open0.00Pre Close0 Volume0 Open Interest70.00Strike Price0.00Turnover75.94%IV-34.97%PremiumSep 20, 2024Expiry Date37.65Intrinsic Value100Multiplier26DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9878Delta0.0015Gamma2.83Leverage Ratio-0.0225Theta0.0484Rho2.80Eff Leverage0.0091Vega
Wintrust Financial Stock Discussion
NEWS
Wintrust Financial Corporation and Macatawa Bank Corporation Announce Plans to Merge
Wintrust Financial and Macatawa Bank have announced a merger agreement for Wintrust to acquire Macatawa in an all-stock transaction. Macatawa, with approximately $2.7 billion in assets, will be acquired for an estimated $510.3 million, or $14.85 per share. The transaction is expected to close in the second half of 2024.
• $DBV Technologies (DBVT.US)$ +23.5% (positive topline results from Phase 3 EPITOPE Trial)
• $Aldeyra Therapeutics (ALDX.US)$ +19.2% (achieves primary endpoint in phase 3 tranquility-2 trial)
• $MediciNova (MNOV.US)$ +11.9% (top-line results from phase 2 clinical trial of MN-166)
• $Torrid (CURV.US)$ +11% (In reaction to earnings/guidance)
• $Novavax (NVAX.US)$ +10.1% (FDA advisory committee recommends EUA for its COVID-19 v...
No comment yet